BCRX Stock: Price, Earnings History and SEC Filings
BioCryst Pharmaceuticals, Inc. (BCRX) last traded at $8.47, down 0.59% on the latest session and up 1.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.30 against an analyst estimate of $0.14, a beat of 114.3%.
$8.47 -0.59%
1 month+1.68%
52-week high$11.22
52-week low$6.23
Volume3.53M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BCRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.30 | $0.14 | +114.29% |
| Mar 2026 | May 6, 2026 | $-0.03 | $0.06 | -150.00% |
| Dec 2025 | Feb 26, 2026 | $1.12 | $0.07 | +1500.00% |
| Sep 2025 | Nov 3, 2025 | $0.06 | $0.07 | -14.29% |
BCRX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for BCRX
SEC filing data is not available right now. You can search for BCRX on SEC EDGAR.
BCRX news
- How New HAE Data At BioCryst Pharmaceuticals Stock Has Changed Its Investment StoryOct 31, 2026 · finance.yahoo.com
- Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Oct 30, 2026 · finance.yahoo.com
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Oct 29, 2026 · finance.yahoo.com
- BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific MeetingOct 29, 2026 · finance.yahoo.com
- BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOct 28, 2026 · finance.yahoo.com
- BioCryst to Report Third Quarter 2026 Financial Results on November 4Oct 21, 2026 · finance.yahoo.com
- BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEOct 21, 2026 · finance.yahoo.com
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (BCRX) is a US-listed public company on Nasdaq.